USA
Analytical Standards
Controlled Research Environment
Research Product
Tesamorelin
1. Product Overview
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that has been extensively studied for its interaction with growth hormone regulatory pathways and endocrine signaling mechanisms. Research involving Tesamorelin has explored its role in metabolic regulation, body composition studies, peptide receptor interactions, and growth hormone-related biological processes. The peptide is supplied as a lyophilized research formulation and undergoes analytical testing to verify identity, purity, and consistency.
Manufactured in a controlled research environment, this product is intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | Tesamorelin | Testing Method | HPLC |
|---|---|---|---|
| Synonym | Tesamorelin peptide profile | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 5 mg per vial | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that has attracted significant scientific interest in studies involving endocrine signaling, growth hormone regulation, metabolic pathways, and peptide receptor interactions. Research has explored its interaction with growth hormone-releasing hormone receptors and its role in growth hormone-related biological processes.
Preclinical and clinical investigations have evaluated Tesamorelin in research involving metabolic regulation, body composition, endocrine function, and neuroendocrine signaling mechanisms. Ongoing studies continue to examine its activity within growth hormone-related pathways and broader metabolic research applications.
4. Scientific References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with abdominal fat accumulation. New England Journal of Medicine. 2007;357(23):2359-2370.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of Tesamorelin on metabolic and endocrine pathways in clinical research. Journal of Clinical Endocrinology & Metabolism. 2014;99(11):E2358-E2366.
- Makimura H, Feldpausch MN, Rope AM, et al. Metabolic and physiological effects of Tesamorelin administration. Journal of Clinical Endocrinology & Metabolism. 2011;96(11):3282-3289.
- Bowers CY. Growth hormone-releasing hormone analogues and endocrine regulation. Endocrine. 1998;8(1):7-11.
- Koutkia P, Grinspoon S. Growth hormone-releasing hormone and metabolic regulation: Emerging research. Trends in Endocrinology & Metabolism. 2004;15(8):404-410.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
